Compare Stocks: MRUS, ROIV, INCY, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INCY Incyte	$129.72 +1.4%	$117.29	$81.09 ▼ $132.60	$25.94B	0.76	1.79 million shs	1.16 million shs
MRUS Merus	$90.00 -7.1%	$93.01	$37.92 ▼ $97.14	$6.83B	1.06	1.51 million shs	2.73 million shs
ROIV Roivant Sciences	$36.47 +0.3%	$34.86	$11.62 ▼ $37.97	$26.26B	1.12	5.78 million shs	4.48 million shs
UTHR United Therapeutics	$518.53 +1.1%	$531.75	$302.19 ▼ $609.35	$22.00B	0.59	530,765 shs	876,492 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INCY Incyte	+1.36%	+5.06%	+10.24%	+33.26%	+53.04%
MRUS Merus	0.00%	0.00%	0.00%	0.00%	+36.90%
ROIV Roivant Sciences	+0.30%	-2.41%	+4.17%	+23.29%	+213.32%
UTHR United Therapeutics	+1.10%	+0.05%	-1.88%	-9.15%	+69.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INCY Incyte	$129.72 +1.4%	$117.29	$81.09 ▼ $132.60	$25.94B	0.76	1.79 million shs	1.16 million shs
MRUS Merus	$90.00 -7.1%	$93.01	$37.92 ▼ $97.14	$6.83B	1.06	1.51 million shs	2.73 million shs
ROIV Roivant Sciences	$36.47 +0.3%	$34.86	$11.62 ▼ $37.97	$26.26B	1.12	5.78 million shs	4.48 million shs
UTHR United Therapeutics	$518.53 +1.1%	$531.75	$302.19 ▼ $609.35	$22.00B	0.59	530,765 shs	876,492 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INCY Incyte	+1.36%	+5.06%	+10.24%	+33.26%	+53.04%
MRUS Merus	0.00%	0.00%	0.00%	0.00%	+36.90%
ROIV Roivant Sciences	+0.30%	-2.41%	+4.17%	+23.29%	+213.32%
UTHR United Therapeutics	+1.10%	+0.05%	-1.88%	-9.15%	+69.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INCY Incyte	2.56	Moderate Buy	$123.10	-5.11% Downside
MRUS Merus	1.93	Reduce	$96.92	7.69% Upside
ROIV Roivant Sciences	2.85	Moderate Buy	$35.14	-3.66% Downside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	24.58% Upside

Current Analyst Ratings Breakdown

Latest MRUS, ROIV, INCY, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	INCY Incyte	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	INCY Incyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	INCY Incyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$152.00
8/20/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$150.00
8/19/2026	ROIV Roivant Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/17/2026	INCY Incyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$110.00 ➝ $130.00
8/13/2026	UTHR United Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/13/2026	INCY Incyte	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$104.00
8/10/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
8/7/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $41.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INCY Incyte	$5.14B	5.11	$6.26 per share	20.71	$31.30 per share	4.14
MRUS Merus	$36.13M	188.94	N/A	N/A	$9.46 per share	9.51
ROIV Roivant Sciences	$8.26M	3,189.23	N/A	N/A	$6.81 per share	5.36
UTHR United Therapeutics	$3.18B	6.99	$33.35 per share	15.55	$149.22 per share	3.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INCY Incyte	$1.29B	$7.85	16.52	16.09	4.05	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
MRUS Merus	-$215.33M	-$5.30	N/A	N/A	N/A	-673.31%	-52.99%	-44.61%	N/A
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	18.55	17.48	1.74	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest MRUS, ROIV, INCY, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INCY Incyte	N/A	4.59	4.51
MRUS Merus	N/A	7.97	7.97
ROIV Roivant Sciences	N/A	16.72	16.72
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INCY Incyte	96.97%
MRUS Merus	96.14%
ROIV Roivant Sciences	64.76%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
INCY Incyte	16.20%
MRUS Merus	3.70%
ROIV Roivant Sciences	8.80%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
MRUS Merus	37	75.85 million	73.04 million	Optionable
ROIV Roivant Sciences	860	722.32 million	658.76 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

MRUS, ROIV, INCY, and UTHR Headlines

Recent News About These Companies

Man Group plc Invests $73.09 Million in United Therapeutics Corporation $UTHR

50 minutes ago | marketbeat.com

Jupiter Topco LLC Invests $450.14 Million in United Therapeutics Corporation $UTHR

1 hour ago | marketbeat.com

OMERS ADMINISTRATION Corp Makes New Investment in United Therapeutics Corporation $UTHR

2 hours ago | marketbeat.com

Elmind Capital LP Invests $8.13 Billion in United Therapeutics Corporation $UTHR

3 hours ago | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,863,715.00 in Stock

August 25 at 5:06 PM | marketbeat.com

Nicholas Investment Partners LP Makes New $3.87 Million Investment in United Therapeutics Corporation $UTHR

August 25 at 6:40 AM | marketbeat.com

Trail Ridge Investment Advisors LLC Invests $1.30 Million in United Therapeutics Corporation $UTHR

August 25 at 5:59 AM | marketbeat.com

L2 Asset Management LLC Invests $5.82 Million in United Therapeutics Corporation $UTHR

August 25 at 5:52 AM | marketbeat.com

Partners Capital Investment Group LLP Purchases New Shares in United Therapeutics Corporation $UTHR

August 25 at 5:44 AM | marketbeat.com

Korea Investment CORP Invests $9.64 Million in United Therapeutics Corporation $UTHR

August 25 at 5:12 AM | marketbeat.com

Callan Family Office LLC Purchases Shares of 2,246 United Therapeutics Corporation $UTHR

August 25 at 3:59 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

August 24 at 5:06 PM | marketbeat.com

United Therapeutics Ralinepag NDA Accepted by FDA With June 2027 Decision Date

August 24 at 2:34 PM | finance.yahoo.com

United Therapeutics Says FDA Accepted Application for Pulmonary Arterial Hypertension Treatment

August 24 at 9:33 AM | finance.yahoo.com

Meiji Yasuda Asset Management Co Ltd. Makes New $5.41 Million Investment in United Therapeutics Corporation $UTHR

August 24 at 6:15 AM | marketbeat.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,342,062.00 in Stock

August 24 at 4:43 AM | americanbankingnews.com

Daiichi Life Insurance Co. Ltd. Buys New Stake in United Therapeutics Corporation $UTHR

August 24 at 4:08 AM | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in United Therapeutics Corporation $UTHR

August 24 at 3:12 AM | marketbeat.com

Kendall Capital Management Purchases Shares of 5,881 United Therapeutics Corporation $UTHR

August 23 at 6:24 AM | marketbeat.com

Ieq Capital LLC Invests $14.14 Million in United Therapeutics Corporation $UTHR

August 23 at 5:36 AM | marketbeat.com

Evolve Private Wealth LLC Acquires Shares of 12,735 United Therapeutics Corporation $UTHR

August 23 at 4:07 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRUS, ROIV, INCY, and UTHR Company Descriptions

Incyte NASDAQ:INCY

$129.72 +1.74 (+1.36%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$129.31 -0.41 (-0.32%)

As of 07:14 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Merus NASDAQ:MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Roivant Sciences NASDAQ:ROIV

$36.47 +0.11 (+0.30%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$36.48 +0.02 (+0.04%)

As of 07:16 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics NASDAQ:UTHR

$518.53 +5.65 (+1.10%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$518.66 +0.13 (+0.02%)

As of 08/25/2026 05:43 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRUS, ROIV, INCY, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRUS, ROIV, INCY, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRUS, ROIV, INCY, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRUS, ROIV, INCY, and UTHR Company Descriptions

Incyte NASDAQ:INCY

Merus NASDAQ:MRUS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MRUS, ROIV, INCY, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MRUS, ROIV, INCY, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MRUS, ROIV, INCY, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRUS, ROIV, INCY, and UTHR Company Descriptions

Incyte NASDAQ:INCY

Merus NASDAQ:MRUS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools